177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an alternative to the more advanced 177Lu-PSMA-617. The peptide is conjugated with a truncated Evans Blue (EB) molecule and DOTA chelator.
177Lu-EB-PSMA-617 is explored in patients with metastatic castration resistant prostate cancer. The drug has the same target population has 177Lu-PSMA-617 and must be considered as a ‘me-too’ compared to this drug.
The first Phase I study was completed during the year 2018. Patients were selected on the basis of 68Ga-PSMA-617. The molecule showed a safety and tolerability profile similar to 177Lu-PSMA-617.
Leading Emitter: beta electrons (β–)